Assertio Holdings, Inc.

Assertio Holdings is a pharmaceutical company with commercial capabilities that offers differentiated products to address patient needs, primarily in the oncology market. The company builds its product portfolio by acquiring or licensing approved products. Its lead product is ROLVEDON, acquired on July 31, 2023, through a merger with Spectrum Pharmaceuticals, Inc. ROLVEDON is a long-acting myeloid growth factor indicated to decrease the incidence of infection, specifically febrile neutropenia, in adult patients receiving anti-cancer drugs. Assertio believes ROLVEDON has opportunities in both hospitals and community oncology clinics. Other products include Sympazan, acquired in October 2022; SPRIX and INDOCIN, acquired through a merger with Zyla Life Sciences in May 2020; and CAMBIA, acquired in December 2013. The company ceased commercialization of Otrexup, which was acquired in December 2021, in July 2025. Assertio Therapeutics, Inc., a subsidiary, was divested on May 9, 2025. Assertio Specialty Pharmaceuticals, LLC and Spectrum Pharmaceuticals, Inc. are wholly-owned subsidiaries.